Is GLP-1R Agonists Effective and Safe in Severe COVID-19 Patients with Type 2 Diabetes? - A Case Report and Literature Review

8 Pages Posted: 29 Jul 2020

See all articles by Shuqian Chen

Shuqian Chen

Fujian Medical University - Department of Endocrinology

Wei Lin

Fujian Medical University - Department of Endocrinology

Junping Weng

Fujian Medical University - Department of Endocrinology

Baosong Xie

Fujian Medical University - Department of Respiratory

Lizhou Chen

Fuzhou Pulmonary Hospital of Fujian - Department of Respiratory Medicine

Gang Chen

Fujian Medical University - Department of Endocrinology; Fujian Academy of Medical Sciences - Fujian Provincial Key Laboratory of Medical Analysis

Date Written: July 17, 2020

Abstract

Hyperglycemia is a risk factor for the severity of COVID-19. Glucagon-like Peptide 1 Receptor (GLP-1R) agonists have been proved to be a safe and effective anti-hyperglycemia drugs. This paper introduces a case of severe COVID-19 patient combined with diabetes and try to study the safety and efficacy of liraglutide in these patients. During treatment, dynamic change of blood glucose level was shown in the Figure 1. Hydroxychloroquine sulfate and abidol was used to antivirus and supportive treatment were used simultaneously during hospitalization. Dynamic change of liver function, renal function, white blood cells, lymphocytes and inflammatory indicators during treatment were shown in Figure 2 and Figure 3. The patient's condition improve gradually, blood glucose was under control, the laboratory test and chest CT also improved after treatment. (Fig4) This case indicates that liraglutide can be safely used in patients with severe COVID-19 combined with type 2 diabetes.

Note: Funding: None.

Conflict of Interest: The authors declare that they have no conflicts of interest for this work.

Suggested Citation

Chen, Shuqian and Lin, Wei and Weng, Junping and Xie, Baosong and Chen, Lizhou and Chen, Gang, Is GLP-1R Agonists Effective and Safe in Severe COVID-19 Patients with Type 2 Diabetes? - A Case Report and Literature Review (July 17, 2020). Available at SSRN: https://ssrn.com/abstract=3654086 or http://dx.doi.org/10.2139/ssrn.3654086

Shuqian Chen

Fujian Medical University - Department of Endocrinology

China

Wei Lin

Fujian Medical University - Department of Endocrinology

China

Junping Weng

Fujian Medical University - Department of Endocrinology

China

Baosong Xie

Fujian Medical University - Department of Respiratory ( email )

Fuzhou
China

Lizhou Chen

Fuzhou Pulmonary Hospital of Fujian - Department of Respiratory Medicine ( email )

Fuzhou, 350008
China

Gang Chen (Contact Author)

Fujian Medical University - Department of Endocrinology ( email )

China
+86-1350933707 (Phone)

Fujian Academy of Medical Sciences - Fujian Provincial Key Laboratory of Medical Analysis

China

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
72
Abstract Views
1,279
Rank
585,331
PlumX Metrics